KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Cash & Equivalents (2016 - 2025)

AbbVie (ABBV) has disclosed Cash & Equivalents for 14 consecutive years, with $5.2 billion as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 5.34% to $5.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.2 billion through Dec 2025, down 5.34% year-over-year, with the annual reading at $5.2 billion for FY2025, 5.34% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $5.2 billion at AbbVie, down from $5.6 billion in the prior quarter.
  • The five-year high for Cash & Equivalents was $18.1 billion in Q1 2024, with the low at $5.2 billion in Q1 2025.
  • Average Cash & Equivalents over 5 years is $9.2 billion, with a median of $8.7 billion recorded in 2021.
  • The sharpest move saw Cash & Equivalents crashed 76.29% in 2021, then surged 169.21% in 2024.
  • Over 5 years, Cash & Equivalents stood at $9.7 billion in 2021, then dropped by 5.59% to $9.2 billion in 2022, then skyrocketed by 39.27% to $12.8 billion in 2023, then tumbled by 56.89% to $5.5 billion in 2024, then dropped by 5.34% to $5.2 billion in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $5.2 billion, $5.6 billion, and $6.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.